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ABSTRACT Pentagamavunone‐0 (PGV‐0) or 2,5‐bis(4’‐hydroxy‐3‐methoxybenzylidine)‐cyclopentanone is a curcumin
analogue that exhibits anticancer activity in breast cancer cells. However, most of previous reports are limited to the use
of two‐dimensional (2D) cell culture. The use of three‐dimensional (3D) cell culture model in cancer research enables to
represent the real condition of cancer growth in patients better than 2D. The purpose of this study was to determine the
anticancer activity of PGV‐0 on a 3D model of HCC 1954 breast cancer cells. HCC 1954 cells were grown and treated
with PGV‐0 for 24 hours (h) and observed using a microscope to determine the effect of PGV‐0 on spheroids formation.
The inhibitory effect of spheroids growth was observed using a lens after the spheroids formation treated by PGV‐0 for 96
h. The cytotoxic effects were measured by MTT assay. PGV‐0 inhibited the formation and growth of spheroids started at
the concentration of 60 µM. The cytotoxic effect of PGV‐0 in a dose‐dependent manner with the IC50 value of 70.9 µM.
The results of this study indicated that PGV‐0 has anticancer activity on a 3D model of HCC 1954 breast cancer cell line.
Therefore, it can be used as a candidate for cancer chemopreventive agent.
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11. Introduction 2
Chemoprevention is the process of preventing or inhibit­ 3
ing the development of cancer by using chemopreventive 4
agents, either natural or synthetic chemical substances) 5
(Meiyanto et al. 2012). Natural compounds are widely 6
used as chemopreventive agents because of their safety, 7
low toxicity, antioxidants, and used as food supplements. 8
Curcumin, epigallocatechin 3­gallate (EGCG), resvera­ 9
trol, sulforaphane, and Withaferin­A are natural com­ 10
pounds that have potential as chemopreventive agents 11
(Pistollato et al. 2017). 12
Pentagamavunone­0 (PGV­0) or 2,5­bis(4’­hydroxy­ 13
3­methoxybenzylidine)­cyclopentanone is an analogue of 14
curcumin. Synthesis of PGV­0 was carried out to increase 15
the solubility level of curcumin in water and maintain its 16
stability at pH>6.5 ??. It was reported to have similar or 17
better anti­inflammatory activities than curcumin. PGV­0 18
can inhibit the growth of T47D breast cancer cells through 19
apoptosis and has anti­proliferative effects on myeloma 20
cells (Da’i et al. 2004, 2007). PGV­0 also shows cy­ 21
totoxic activity in WiDr colon cancer cells (Septisetyani 22
et al. 2008), and MCF­7 breast cancer cells (Hermawan et 23
al. 2011). The previously reported anti­cancer research of 24
PGV­0 is limited to the use of two­dimensional (2D) cell 25
culture and had not been carried out on three­dimensional 26
(3D) cell culture. 27
The 3D cell culture performs better abilities to rep­ 28
resent the real condition of cancer cells in the patients 29
compared to the 2D culture. These better abilities in­ 30
clude cell morphology, cell­cell communication, gene ex­ 31
pression, and biological and stress response (Boutin et al. 32
2018). In 2D cell cultures, cancer cells stick and grow on 33
a flat surface so that consisting one layer of proliferation 34
cells. While cancer cells in 3D cultures form aggregates 35
or spheroids, 3D­shaped cancer cells, consisting of prolif­ 36
eration, quiescent, and necrotic zones (Edmondson et al. 37
2014). Concerning the stress response, the 3D model is 38
also suitable to explore the resistance characteristic or stem 39
cell­like phenomena. 40
The physiological mechanism of PGV­0 as a candi­ 41
date for chemopreventive agent needs to be explored fur­ 42
ther, mainly focusing on the stress response. Curcumin has 43
been widely explored for its cytotoxic activities to many 44
types of cancer cells. The high selectivity of curcumin 45
to cancer cells rather than normal cells possibly correlates 46
with the inhibitory activities against some ROSmetaboliz­ 47
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ing enzymes that contribute to the induction of cell apopto­ 48
sis as well as cell migration (Larasati et al. 2018). There­ 49
fore, PGV­0 may have the same mechanism as curcumin 50
that triggers cell death in a 3D system. This research was 51
carried out to determine the biological activity of PGV­0 52
as a candidate for chemopreventive agents for breast can­ 53
cer by using HCC 1954 breast cancer cells in a 3D model. 54
55
2. Materials and Methods 56
2.1. Materials 57
Curcumin and PGV­0 in powder formswere obtained from 58
Cancer Chemoprevention Research Center (CCRC), Fac­ 59
ulty of Pharmacy, Universitas Gadjah Mada, Indonesia. 60
Curcumin (271.5 mM) and PGV­0 (283.8 mM) stock solu­ 61
tions were prepared by dissolving them in dimethyl sulfox­ 62
ide (DMSO) (Sigma Aldrich). The stock solutions were 63
then dissolved in culture medium at a serial concentration 64
(10, 20, 30, 60, 80, and 160 µM) to treat the cancer cells. 65
2.2. Cell culture 66
HCC 1954 breast cancer cell line, given by Dr. med. 67
Muhammad Hasan Bashari, M.D., M.Kes., Universitas 68
Padjadjaran, Indonesia, was grown in the RPMI (Gibco) 69
medium supplemented with 10% v/v FBS (Sigma) and 1% 70
v/v penicillin­streptomycin (Gibco) (Bashari et al. 2019). 71
The cells were incubated in an incubator with 5% CO2 at 72
37 ￿. At 80% confluence, cells were harvested by using 73
0.025% trypsin­EDTA (Gibco). 74
2.3. Spheroid formation 75
The formation of spheroids was carried out by growing 76
HCC 1954 cells (9x103 cells/well) in the RPMI medium 77
on 96­well plates that had been coated with 1.5% agarose 78
matrix (Sigma). The cells were incubated for 96 h until 79
the spheroids were formed and ready to be used for exper­ 80
iments (Bashari et al. 2019). The spheroids were observed 81
their morphological appearance using an inverted micro­ 82
scope (Boeco) at 24, 48, 72, and 96 h. The diameter of the 83
spheroids was measured using Image Raster 3.0 software 84
while the density of the spheroids was measured using Im­ 85
ageJ software. 86
2.4. Inhibitory effect of spheroids formation 87
The effect of PGV­0 and curcumin on the growth of 88
spheroids could be observed after the spheroids had been 89
formed. The spheroids were treated with PGV­0 or cur­ 90
cumin at a serial concentration and incubated for 96 h. 91
During the incubation period, the spheroids were observed 92
using an inverted microscope (Boeco) at 0, 24, 48, 72, and 93
96 h. 94
2.5. Cytotoxicity assay 95
The cytotoxic effect of PGV­0 and curcumin were mea­ 96
sured using MTT assay according to the previous report 97
(Ho et al. 2012) with a slight modification to the proto­ 98
col. Briefly, the spheroids which had been treated with 99
PGV­0 or curcumin for 96 h were then transferred to 100
a new 96­well plate using a micropipette. Ten micro­ 101
liters of MTT reagents were added to each well­containing 102
spheroid in 90 µL of the transferred medium. The reaction 103
was stopped by adding an SDS stopper solution containing 104
0.01N HCl to the spheroids that had been incubated for 4 105
h. Furthermore, the spheroids were incubated overnight at 106
room temperature in a dark place. Absorbance was mea­ 107
sured using an ELISA reader with a wavelength of 595 nm. 108
Percentage of the cell viability was calculated to determine 109
IC50 values by a linear regression analysis (Ikawati et al. 110
2009). 111
3. Results and Discussion 112
3.1. Results 113
3.1.1 Spheroid formation 114
The spheroids of HCC 1954 breast cancer began to form 115
at 24 h, but the compactness was relatively low. The com­ 116
pactness increased as the incubation time increased. It 117
caused a decrease in the diameter of spheroids during the 118
incubation period (Figure 11B). The highest reduction of 119
spheroids diameter was occurred from the 24 h to 48 h, 120
which was 7%, while the total decrease in spheroids di­ 121
ameter during the incubation period was 12% (Figure 1C). 122
The cohesiveness of spheroids was obtained by measuring 123
the spheroid density based on the color of the observed im­ 124
ages. The color of spheroids was getting darker during the 125
incubation period (Figure 1A), whichmeans that the thick­ 126
ness of the spheroids was increasing (Figure 1D). 127
3.1.2 PGV­0 inhibits spheroid formation 128
Spheroids were formed after incubation for 24 h (Figure 129
2A). PGV­0 began to inhibit the formation of spheroids 130
started at 60 µM. It could be seen that at this concentra­ 131
tion, HCC 1954 cells could not form compact aggregates. 132
Some HCC 1954 cells partially scattered at the edge of 133
non­compact aggregates as a single cell (Figure 2B). Un­ 134
der 60 µM, PGV­0 resulted in spheroids with the cohesive­ 135
ness decrease as the increase of the concentrations. Cur­ 136
cumin could inhibit the formation of spheroids at a lower 137
concentration than PGV­0, which is 30 µM. At this con­ 138
centration, HCC 1954 cells formed smaller compact ag­ 139
gregates than untreated spheroids and were surrounded by 140
non­compact aggregates. 141
3.1.3 PGV­0 inhibits spheroid growth 142
The data showed that PGV­0 and curcumin resulted in the 143
spheroids experiencing a decrease and an increase in diam­ 144
eter (Figure 3A). PGV­0 increased the spheroids diameter 145
at a concentration of 60 μM while curcumin at a concen­ 146
tration of 30 μM (Figure 3B). The highest total reduction 147
in spheroids diameter was 4% by PGV­0 while the high­ 148
est increase caused by curcumin treatment which was 8% 149
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FIGURE 1 Spheroids formation of HCC 1954 cells. (A) HCC 1954 cells (9x103 cells/well) were grown in a 96‐well plate coated with 1.5%
agarose matrix. The formation of the spheroids was observed using an inverted microscope up to 96 h. (B) The diameter of the spheroids
was measured using Image Raster 3.0 software and (C) the decrease in diameter was measured at the indicated time. (D) The density of
the spheroids was measured using ImageJ software. Each point on B, C, and D was measured from three wells and is presented as mean ±
standard deviation. The asterisk (*) indicated p<0.05, n = 3.
FIGURE 2 Inhibition of spheroid formation by PGV‐0 or curcumin at 24 hours. (A) HCC 1954 cells (9x103 cells/well) were grown and treated
with PGV‐0 or curcumin at a serial concentration for 24 h until spheroids formed. Figures depicted at 0 h after spheroid formation. (B) After
24 h of spheroid formation, the inhibitory effect of PGV‐0 started to be seen at a concentration of 60 µM.
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FIGURE 3 Effect of PGV‐0 or curcumin on the spheroids of HCC 1954 cells. (A) HCC 1954 spheroids that have been formed, subsequently
were treated by PGV‐0 or curcumin at a serial concentration for 96 h. (B and C) The spheroids diameter was measured using Image Raster
3.0 software. (D) The density of the spheroids was measured using ImageJ software. Each point on B, C, and D was measured from three
wells and is presented as mean ± standard deviation.
FIGURE 4 The cytotoxic effect of PGV‐0 or curcumin on the HCC 1954 spheroids. The formed spheroids were treated by PGV‐0 or curcumin
for 96 h. Cell viability wasmeasured usingMTT assay in triplicate. The cytotoxic effects of PGV‐0 or curcuminwere shown by the percentage
of cell viability (mean ± standard deviation).
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(Figure 3C). Besides, it was seen that the spheroids den­ 150
sity tends to decrease by the PGV­0 treatment, whereas in 151
curcumin, the cell density was relatively the same (Figure 152
3D). 153
3.1.4 PGV­0 has cytotoxic activity on spheroids 154
The cytotoxic activity of PGV­0 and curcumin in spheroids 155
was measured by MTT assay. PGV­0 and curcumin per­ 156
formed a cytotoxic effect on a dose­dependent manner in 157
HCC 1954 breast cancer cells with the IC50 of 70.9 µM 158
and 60.6 µM, respectively (Figure 4). 159
3.2. Discussion 160
This study aimed to determine the anticancer activity 161
of PGV­0 on a 3D model of HCC 1954 breast cancer 162
cells by inhibiting the formation, growth, and viability 163
of spheroids. Therefore, it was started by growing the 164
spheroids without being treated to find out the period of 165
spheroids to be formed, the incubation period of spheroids, 166
and the spheroids appearance during the incubation period. 167
The result showed that spheroids began to be formed at 24 168
h with the compactness increased as the incubation period 169
increased. It was indicated by the decreasing diameter and 170
increasing density of spheroids during 96 h of incubation. 171
Spheroids were ready to use after being incubated for 96 h 172
following the previous studies (Bashari et al. 2019). The 173
spheroids were ready to use when there was a decrease in 174
diameter, but the size of the spheroids was relatively the 175
same. 176
The use of 2D culture in cancer research has limita­ 177
tions as it consists of one layer of cells so that it cannot rep­ 178
resent the real condition of cells in patients which consists 179
of several layers of cells. The 3D cell culture has a better 180
ability to represent cell morphology, cell­cell communica­ 181
tion, gene expression, and biological response compared 182
to 2D culture (Boutin et al. 2018). In this study, PGV­0 has 183
tested on 3D models of HCC 1954 cells. Besides PGV­0, 184
curcumin was also used in this study as a comparison. 185
The results indicated that PGV­0 could inhibit the for­ 186
mation of spheroids, starting at a concentration of 60 µM. 187
The inhibitory effect on spheroids increased as the con­ 188
centration increased. Curcumin treatment at a serial con­ 189
centration (0­160 µM) started to inhibit at a concentra­ 190
tion of 30 µM. Although curcumin was able to inhibit at 191
a lower concentration than PGV­0, the aggregates com­ 192
ing from PGV­0 treatment were more easily destroyed by 193
pipetting. It was shown that PGV­0 had a better ability 194
to reduce adhesion between cancer cells than curcumin. 195
Epithelial­cadherin (E­cadherin) is a transmembrane gly­ 196
coprotein that has a pivotal role in maintaining cell to cell 197
adhesion (Liu and Chu 2014). The inhibitory effect on 198
spheroids formation might be caused of PGV­0 and cur­ 199
cumin effects on the E­cadherin expression. However, the 200
molecular mechanism of this phenomenon needs to be ex­ 201
plored further. 202
PGV­0 showed the ability to inhibit the growth of 203
spheroids by decreasing and increasing the diameter. The 204
spheroids diameter started to increaseat a concentration 205
of 60 µM. Furthermore, the inhibitory effect of spheroids 206
growth had not been seen under a concentration of 60 207
µM. This can be occurred because the spheroids were 208
experiencing asame condition as untreated spheroids that 209
were decreasing in diameter. Besides, the cohesiveness of 210
spheroid increased, and only cells in the outer part of the 211
spheroids began to detach. In contrast, an increase of the 212
spheroid diameter was caused by a decrease in adhesion 213
between cells due to PGV­0 so that the cells detach in all 214
parts of the spheroids. The reduced sticking ability be­ 215
tween cells resulted in decreased spheroids cohesiveness. 216
This result also happened to the treatment with curcumin, 217
but at a lower concentration of 30 µM. 218
The previous study reported that single treatment of 219
PGV­0 exhibited anticancer activities in several types 220
of 2D breast cancer cells, namely T47D (Da’i et al. 221
2007), MCF­7 (Hermawan et al. 2011), andMCF­7/HER2 222
(Meiyanto et al. 2014). In combination with other 223
chemotherapy agents, PGV­0 enhanced their cytotoxic ef­ 224
fects in a 2D model of MCF­7 and WiDr cells (Hermawan 225
et al. 2011; ?) so that it could be the candidate of a co­ 226
chemotherapy agent. This study showed that the treat­ 227
ment of PGV­0 performed cytotoxic effects on spheroids 228
of HCC 1954 breast cancer cells with the IC50 value of 229
70.9 µM. This value was about twice the IC50 of PGV­0 230
in 2Dmodels of HCC 1954 cells (CCRC unpublished data, 231
2019). PGV­0 affected spheroids with a higher concentra­ 232
tion than monolayer cells because the spheroids consisted 233
of several layers so that the toxic effects were not evenly 234
distributed on all cells. The outermost part of spheroids 235
obtained greater influence than the inner part (Sant and 236
Johnston 2017). The toxic effects increased as the concen­ 237
tration increased meant that the higher the concentration, 238
the fewer the number of living cells. Meanwhile, the treat­ 239
ment of curcumin at the same serial concentration (0­100 240
mΜ) had an IC50 value of 60.6 μM. The results showed 241
that curcumin had a higher cytotoxic effect on a 3D model 242
of HCC 1954 cells than PGV­0. However, PGV­0 and cur­ 243
cumin had a cytotoxic activity at an intermediate level in 244
the range of 21­200 µM. 245
In this study, it was seen that curcumin performed a 246
better effect than PGV­0 as it affected the spheroids at a 247
lower concentration. Anticancer activity of PGV­0 was 248
not always better than curcumin in all types of cancer cells. 249
In WiDr colon cancer cells, curcumin had a higher cyto­ 250
toxic effect than PGV­0 with an IC50 value of 27 μM; 251
while PGV­0 is 45 μM (Septisetyani et al. 2008). Cur­ 252
cumin has been well known to have anticancer activity 253
(Meiyanto 1999). It was proven to inhibit the growth of 254
cancer cells by inducing apoptosis (Da’i et al. 2017) and 255
increasing ROS levels beyond the threshold (Larasati et al. 256
2018). Therefore, PGV­0 probably inhibited the growth of 257
cancer cells in the same pathway as curcumin. PGV­0 still 258
has an opportunity to be used as a candidate of chemo­ 259
preventive agent for breast cancer treatment because the 260
active concentration is similar to curcumin but has more 261
stable and better bioavailability than curcumin. Neverthe­ 262
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less, further investigation is needed to reveal the molecular 263
mechanism of cells death caused by PGV­0. 264
4. Conclusions 265
PGV­0 performed the anticancer activity in the 3D model 266
of HCC 1954 breast cancer cell line. It was seen from the 267
ability of PGV­0 to inhibit the formation and growth of 268
spheroids and its toxic effect. Based on the results, PGV­0 269
can be used as a candidate of chemopreventive agent for 270
breast cancer treatment. 271
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